Efanesoctocog alfa

Efanesoctocog alfa
Clinical data
Trade namesAltuviiio
Other namesBIVV001; antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
License data
Routes of
administration		Intravenous
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC13690H20958N3682O4376S136
Molar mass311501.81 g·mol−1

Efanesoctocog alfa, sold under the brand name Altuviiio, is a medication used for the treatment of hemophilia A (congenital factor VIII deficiency).[1][2]

Efanesoctocog alfa was approved for medical use in the United States in February 2023.[1][2][3][4]

Medical uses

Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.[1][2]

References

  1. 1 2 3 4 "Altuviiio (antihemophilic factor- recombinant, fc-vwf-xten fusion protein-ehtl kit". DailyMed. 31 March 2023. Retrieved 7 May 2023.
  2. 1 2 3 "Altuviiio". U.S. Food and Drug Administration. 21 March 2023. Retrieved 7 May 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ↑ AB, Swedish Orphan Biovitrum (24 February 2023). "FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB" (Press release). Swedish Orphan Biovitrum AB. Retrieved 7 May 2023 – via PR Newswire.
  4. ↑ "Press Release: FDA approves once-weekly Altuviiio, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection" (Press release). Sanofi. 23 February 2023. Retrieved 7 May 2023.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.